LSX World Congress w/ Mark Davies

Join our SVP of Informatics and Data, Mark Davies, at the LSX World Congress.

Drug discovery is ripe for disruption. A time consuming and expensive process, taking years and costing billions, the industry is crying out for faster and more accurate drug targets to test at clinical trials. However technology has not been able to keep up, until now. A panel of leaders discuss the future possibilities and applications, moderated by Steve Carney, Editor at Drug Discovery Today. Speakers include: 

  • Mark Davies, SVP Informatics and Data, Benevolent AI
  • Martin-Immanuel Bittner, CEO, Arctoris
  • Neil Sahota, United Nations Artificial Intelligence Advisor and Interim CEO ACSILabs
  • Marta Gaia Zanchi, Founder and Managing Partner, Nina Capital


  • The role in cost cutting of new drug spend and development times – how big of an impact can AI have in time and cost saving?
  • Should biopharma companies be planning for a future in where AI is routinely used in discovery?
  • AI collaboration to target, identify and diagnose faster
  • Gaining insights from clinical trial data – should everyone be taking a data science approach to clinical trials, and how?

Panel title: How AI, machine learning & big data are disrupting the drug discovery & development landscape for faster and more accurate lead identification

Date: Wednesday May 11th  

Time: 14.00-14.45

Mark Davies

SVP Informatics and Data

He has a background in molecular genetics and bioinformatics and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Projects and eventually moved on to building Chemogenomics systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI) as one of the founding members and technical lead for the ChEMBL resource - the largest open-source SAR database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI

More Posts

You Might Also Like

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022